Expression O
of O
dopamine O
D2 O
and O
D3 O
receptors O
in O
the O
human O
retina O
revealed O
by O
positron O
emission O
tomography O
and O
targeted O
mass O
spectrometry O
Dopamine O
D2 O
receptors O
( O
D2R O
) O
are O
expressed O
in O
the O
human O
retina O
and O
play O
an O
important O
role O
in O
the O
modulation O
of O
neural O
responses O
to O
light-adaptation O
. O

However O
, O
it O
is O
unknown O
whether O
dopamine O
D3 O
receptors O
( O
D3R O
) O
are O
expressed O
in O
the O
human O
retina O
. O

Using O
positron O
emission O
tomography O
( O
PET O
) O
, O
we O
have O
observed O
significant O
uptake O
of O
the O
D3R-preferring O
agonist O
radiotracer O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
into O
the O
retina O
of O
humans O
in O
vivo O
. O

This O
led O
us O
to O
examine O
whether O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
binding O
in O
the O
retina O
was O
quantifiable O
using O
reference O
tissue O
methods O
and O
if O
D3R O
are O
expressed O
in O
human O
post-mortem O
retinal O
tissue O
. O

[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
data O
from O
49 O
healthy O
controls O
( O
mean O
age O
: O
39.96 O
± O
14.36 O
; O
16 O
female O
) O
and O
12 O
antipsychotic-naïve O
patients O
with O
schizophrenia O
( O
mean O
age O
: O
25.75 O
± O
6.25 O
; O
4 O
female O
) O
were O
analyzed O
. O

We O
observed O
no O
differences O
in O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
binding O
in O
the O
retina O
between O
first-episode O
, O
drug-naïve O
patients O
with O
schizophrenia O
and O
healthy O
controls O
. O

Post-mortem O
retinal O
tissues O
from O
four O
healthy O
persons O
( O
mean O
age O
: O
59.75 O
± O
9.11 O
; O
2 O
female O
) O
and O
four O
patients O
with O
schizophrenia O
( O
mean O
age O
: O
54 O
± O
17.11 O
; O
2 O
female O
) O
were O
analyzed O
using O
a O
targeted O
mass O
spectrometry O
technique O
: O
parallel O
reaction O
monitoring O
( O
PRM O
) O
analysis O
. O

Using O
targeted O
mass O
spectrometry O
, O
we O
confirmed O
that O
D3R O
are O
expressed O
in O
human O
retinal O
tissue O
ex O
vivo O
. O

Notably O
, O
there O
was O
far O
greater O
expression O
of O
D2R O
relative O
to O
D3R O
in O
the O
healthy O
human O
retina O
( O
~12:1 O
) O
. O

Moreover O
, O
PRM O
analysis O
revealed O
reduced O
D2R O
, O
but O
not O
D3R O
, O
expression O
in O
the O
retinas O
of O
non-first O
episode O
patients O
with O
schizophrenia O
compared O
to O
healthy O
controls O
. O

We O
confirm O
that O
D3R O
are O
expressed O
in O
the O
human O
retina O
. O

Future O
studies O
are O
needed O
to O
determine O
what O
proportion O
of O
the O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
signal O
in O
the O
human O
retina O
in O
vivo O
is O
due O
to O
binding O
to O
D3R O
versus O
D2R O
. O

Knowledge O
that O
both O
D2R O
and O
D3R O
are O
expressed O
in O
the O
human O
retina O
, O
and O
potentially O
quantifiable O
in O
vivo O
using O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
, O
poses O
new O
research O
avenues O
for O
better O
understanding O
the O
role O
of O
retinal O
dopamine O
in O
human O
vision O
. O

This O
work O
may O
have O
important O
implications O
for O
elucidating O
pathophysiological O
and O
antipsychotic O
induced O
visual O
deficits O
in O
schizophrenia O
. O

2 O
. O

Material O
and O
methods O
2.1 O
. O

[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
participants O
PET O
data O
from O
healthy O
persons O
and O
drug-naive O
persons O
with O
schizophrenia O
, O
previously O
reported O
in O
the O
literature O
, O
were O
re-analyzed O
for O
the O
current O
investigation O
. O

These O
studies O
were O
approved O
by O
the O
Research O
Ethics O
Board O
of O
the O
Centre O
for O
Addiction O
and O
Mental O
Health O
( O
CAMH O
) O
, O
Toronto O
. O

Healthy O
participants O
were O
right-handed O
adults O
free O
of O
any O
major O
medical O
or O
psychiatric O
disorders O
as O
determined O
by O
clinical O
interview O
, O
the O
Mini O
International O
Neuropsychiatric O
Interview-Plus O
( O
MINI-Plus O
) O
, O
basic O
clinical O
laboratory O
tests O
, O
and O
electrocardiography O
. O

Participants O
with O
schizophrenia O
were O
antipsychotic-naïve O
and O
met O
criteria O
for O
the O
diagnosis O
of O
schizophrenia O
or O
schizoaffective O
disorder O
based O
on O
the O
DSM-IV O
and O
the O
MINI-Plus O
. O

Participants O
were O
excluded O
if O
they O
had O
a O
current O
diagnosis O
of O
substance O
abuse O
or O
dependence O
, O
a O
history O
of O
clinically O
significant O
physical O
illness O
, O
or O
metal O
implants O
precluding O
the O
ability O
to O
be O
scanned O
with O
MRI O
. O

At O
inclusion O
and O
before O
the O
PET O
scan O
, O
participants O
were O
required O
to O
have O
a O
negative O
urine O
screen O
for O
drugs O
of O
abuse O
and/or O
pregnancy O
. O

All O
participants O
provided O
written O
informed O
consent O
. O

The O
average O
age O
of O
illness O
onset O
for O
the O
patient O
sample O
was O
24.42 O
± O
6.75 O
( O
range O
: O
17–42 O
) O
, O
with O
an O
average O
duration O
of O
illness O
of O
16.33 O
± O
14.74 O
( O
range O
: O
2–48 O
) O
months O
. O

2.2 O
. O

[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
synthesis O
& O
acquisition O
A O
full O
description O
of O
the O
radiosynthesis O
of O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
, O
as O
well O
as O
how O
PET O
images O
were O
acquired O
, O
can O
be O
found O
in O
previous O
publications O
. O

Briefly O
, O
[ O
11C O
] O
-propionyl O
chloride O
was O
reacted O
with O
9-hydroxynaph-thoxazine O
to O
generate O
a O
[ O
11C O
] O
-amide O
. O

This O
was O
subsequently O
reduced O
by O
lithium O
aluminium O
hydride O
. O

Purification O
by O
HPLC O
and O
formulation O
gave O
radio-chemically O
pure O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
as O
a O
sterile O
, O
pyrogen-free O
solution O
. O

PET O
images O
were O
acquired O
using O
a O
high-resolution O
head-dedicated O
PET O
camera O
system O
( O
CPS-HRRT O
; O
Siemens O
Molecular O
Imaging O
, O
USA O
) O
. O

The O
CPS-HRRT O
measures O
radioactivity O
in O
207 O
brain O
slices O
, O
each O
with O
a O
thickness O
of O
1.2 O
mm O
. O

The O
in-plane O
resolution O
was O
approximately O
2.8 O
mm O
full-width O
at O
half-maximum O
( O
FWHM O
) O
. O

Notably O
, O
significant O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
uptake O
into O
the O
retina O
could O
not O
be O
observed O
on O
scans O
collected O
using O
a O
high-resolution O
PET O
CT O
, O
Siemens-Biograph O
HiRez O
XVI O
( O
Siemens O
Molecular O
Imaging O
, O
Knoxville O
, O
TN O
, O
USA O
) O
operating O
in O
3D O
mode O
with O
an O
in-plane O
resolution O
of O
approximately O
4.6 O
mm O
FWHM O
( O
almost O
half O
the O
resolution O
of O
the O
CPS-HRRT O
) O
. O

Thus O
, O
PET O
camera O
systems O
of O
~2.8 O
mm O
FWHM O
or O
better O
are O
likely O
required O
to O
have O
the O
appropriate O
resolution O
to O
image O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
uptake O
into O
the O
retina O
. O

Transmission O
scans O
were O
acquired O
using O
a O
137Cs O
( O
T1/2=30.2 O
yr O
, O
E=662 O
KeV O
) O
single O
photon O
point O
source O
to O
provide O
attenuation O
correction O
, O
and O
the O
emission O
data O
were O
acquired O
in O
list O
mode O
. O

The O
raw O
data O
were O
reconstructed O
by O
filtered-back O
projection O
and O
the O
emission O
data O
were O
re-binned O
into O
a O
series O
of O
3D O
sonograms O
. O

Scanning O
time O
was O
90-min O
in O
length O
, O
wherein O
30 O
frames O
were O
defined O
: O
1 O
to O
15 O
of O
1-min O
duration O
and O
16 O
to O
30 O
of O
5-min O
duration O
. O

A O
custom-fitted O
thermoplastic O
mask O
( O
Tru-Scan O
Imaging O
, O
Annapolis O
) O
was O
created O
for O
each O
subject O
and O
used O
with O
a O
head O
fixation O
system O
during O
PET O
scans O
to O
reduce O
movement O
during O
the O
acquisition O
. O

[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
was O
injected O
as O
a O
bolus O
followed O
by O
a O
flush O
of O
2 O
mL O
saline O
into O
an O
intravenous O
line O
placed O
in O
an O
antecubital O
vein O
. O

The O
mean O
radioactivity O
dose O
was O
9.38 O
( O
±1.34 O
) O
mCi O
, O
with O
a O
specific O
activity O
of O
1160.82 O
( O
±401.58 O
) O
mCi/µmol O
, O
an O
injected O
mass O
of O
2.07 O
( O
±0.46 O
) O
µg O
, O
and O
an O
injected O
mass O
per O
kilogram O
of O
0.03 O
( O
±0.008 O
) O
µg/Kg O
. O

None O
of O
the O
participants O
included O
in O
this O
sample O
reported O
nausea O
associated O
with O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
injection O
. O

2.3 O
. O

MRI O
imaging O
Subjects O
provided O
a O
T1-weighted O
MRI O
image O
( O
TE=17 O
, O
TR=6000 O
, O
FOV=22 O
cm O
2D O
, O
256×256 O
, O
slice O
thickness O
of O
2 O
mm O
, O
NEX=2 O
) O
acquired O
on O
a O
1.5 O
T O
Signa O
scanner O
( O
General O
Electric O
Medical O
Systems O
, O
Milwaukee O
, O
WI O
) O
. O

These O
images O
were O
used O
to O
enhance O
the O
analysis O
of O
PET O
scans O
, O
via O
co-registration O
( O
described O
in O
detail O
below O
, O
under O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
Image O
Analyses O
) O
. O

2.4 O
. O

[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
Image O
Analyses O
Two O
complementary O
approaches O
were O
employed O
for O
quantifying O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
binding O
in O
the O
retina O
. O

For O
the O
first O
approach O
( O
termed O
“ O
manual O
” O
) O
, O
retina O
ROIs O
were O
drawn O
manually O
on O
each O
subjects O
averaged O
dynamic O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
image O
in O
native-space O
( O
on O
every O
slice O
where O
the O
retina O
could O
be O
observed O
) O
, O
employing O
previous O
PET O
guidelines O
( O
See O
Fig O
. O

2 O
) O
. O

These O
manually O
drawn O
ROIs O
were O
then O
used O
to O
extract O
time O
activity O
curves O
from O
each O
subjects O
' O
dynamic O
PET O
image O
in O
native-space O
( O
See O
Fig O
. O

3 O
) O
. O

This O
was O
done O
with O
reference O
to O
each O
subjects O
co-registered O
T1-weighted O
MRI O
image O
, O
to O
confirm O
the O
placement O
of O
the O
retina O
ROIs O
. O

The O
co-registration O
of O
each O
subjects O
MRI O
to O
PET O
space O
was O
done O
using O
the O
normalized O
mutual O
information O
algorithm O
as O
implemented O
in O
SPM2 O
( O
SPM2 O
, O
Wellcome O
Department O
of O
Cognitive O
Neurology O
, O
London O
; O
http O
: O
//www.fil.ion.ucl.ac.uk/spm O
) O
. O

The O
TACs O
from O
the O
manually O
drawn O
retina O
ROIs O
were O
analyzed O
using O
both O
the O
Simplified O
Reference O
Tissue O
Method O
( O
SRTM O
) O
and O
Ichise O
's O
Multilinear O
Reference O
Tissue O
Model O
( O
MRTM O
) O
, O
both O
of O
which O
have O
been O
validated O
for O
use O
with O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
. O

For O
both O
models O
, O
the O
cerebellum O
was O
used O
as O
the O
reference O
region O
to O
derive O
a O
quantitative O
estimate O
of O
binding O
– O
binding O
potential O
relative O
to O
the O
non-displaceable O
compartment O
( O
BPND O
) O
– O
as O
defined O
by O
the O
consensus O
nomenclature O
for O
in O
vivo O
imaging O
of O
reversibly O
binding O
radioligands O
. O

It O
has O
been O
noted O
for O
in O
vivo O
human O
studies O
with O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
that O
there O
is O
a O
small O
displaceable O
signal O
in O
cerebellum O
( O
BPND=~0.4 O
) O
representing O
binding O
to O
D3R O
in O
cerebellar O
lobes O
IX O
and O
X O
. O

Thus O
, O
while O
we O
have O
done O
our O
best O
to O
exclude O
lobes O
IX O
and O
X O
in O
our O
cerebellar O
ROI O
, O
using O
the O
cerebellum O
as O
the O
reference O
region O
with O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
may O
result O
in O
some O
underestimation O
of O
BPND O
at O
D3R O
. O

Moreover O
, O
we O
recognize O
that O
use O
of O
the O
SRTM O
and O
MRTM O
is O
predicated O
on O
the O
assumption O
that O
blood O
flow O
into O
and O
out O
of O
the O
target O
and O
reference O
regions O
are O
similar O
. O

This O
assumption O
may O
not O
be O
true O
for O
both O
the O
blood-brain O
barrier O
( O
cerebellar O
reference O
region O
) O
and O
the O
retina-brain O
barrier O
( O
retina O
target O
region O
) O
, O
thus O
biasing O
our O
estimate O
of O
BPND O
. O

This O
poses O
a O
limitation O
in O
quantification O
which O
can O
only O
be O
avoided O
using O
arterial O
sampling O
of O
[ O
11C O
] O
- O
( O
+ O
) O
-PHNO O
, O
which O
is O
both O
invasive O
and O
costly O
. O

For O
the O
second O
approach O
( O
termed O
“ O
automated O
” O
) O
, O
the O
basis O
function O
implementation O
of O
the O
SRTM O
was O
applied O
to O
the O
dynamic O
PET O
images O
to O
generate O
parametric O
voxel-wise O
BPND O
maps O
using O
PMOD O
( O
v2.7 O
, O
PMOD O
Technologies O
, O
Zurich O
, O
Switzerland O
) O
. O

These O
images O
were O
spatially O
normalized O
into O
MNI O
brain O
space O
by O
Nearest O
Neighbour O
Interpolation O
with O
a O
voxel O
size O
fixed O
in O
2 O
× O
2 O
× O
2 O
mm3 O
using O
SPM2 O
. O

Regional O
BPND O
estimates O
were O
then O
derived O
from O
a O
manually O
drawn O
retina O
ROI O
defined O
in O
MNI O
space O
. O

The O
drawing O
of O
this O
ROI O
was O
aided O
by O
superimposing O
the O
average O
of O
the O
parametric O
voxel-wise O
BPND O
maps O
of O
all O
the O
subjects O
onto O
an O
MNI O
template O
. O

2.5 O
. O

Post-mortem O
retinal O
tissue O
samples O
Post-mortem O
retinal O
tissues O
from O
four O
patients O
with O
schizophrenia O
, O
and O
four O
age- O
and O
sex-matched O
healthy O
controls O
, O
were O
acquired O
from O
the O
St. O
Michael O
's O
Hospital O
Human O
Eye O
Biobank O
( O
http O
: O
//www.stmichaelshospital.com/eye-biobank/ O
; O
Toronto O
, O
Ontario O
, O
Canada O
) O
( O
See O
Table O
3 O
) O
. O

Samples O
were O
formalin-fixed O
paraffin-embedded O
( O
FFPE O
) O
. O

2.6 O
. O

Sample O
preparation O
and O
high-resolution O
parallel O
reaction O
monitoring O
( O
PRM O
) O
analyses O
Total O
sample O
homogenates O
( O
approx O
. O

2 O
µg O
) O
were O
subjected O
to O
a O
modified O
filter-aided O
sample O
preparation O
( O
FASP O
) O
protocol O
as O
previously O
described O
, O
with O
additional O
precipitation O
using O
an O
equal O
volume O
of O
2M O
KCL O
for O
depletion O
of O
residual O
detergents O
. O

Lys-C O
and O
tryptic O
peptides O
were O
combined O
and O
processed O
on O
Pierce O
C18 O
Tips O
reversed O
phase O
resin O
( O
Thermo O
Scientific O
) O
for O
desalting O
and O
concentration O
. O

High-resolution O
parallel O
reaction O
monitoring O
( O
HR-PRM O
) O
analyses O
were O
performed O
on O
a O
Q O
Exactive O
HF O
quadrupole–orbitrap O
mass O
spectrometer O
( O
Thermo O
Fisher O
Scientific O
) O
coupled O
to O
an O
EASY O
nanoflow O
liquid O
chromatography O
( O
EASY-nLC™ O
) O
system O
( O
Thermo O
Fisher O
Scientific O
) O
. O

Peptides O
were O
separated O
on O
a O
50 O
cm O
column O
( O
75 O
µm O
inner O
diameter O
) O
packed O
with O
PepMap®RSLC O
C18 O
resin O
at O
60 O
°C O
, O
using O
a O
flow O
rate O
of O
250 O
nl/min O
on O
a O
0 O
% O
–42 O
% O
acetonitrile O
( O
ACN O
) O
in O
0.1 O
% O
formic O
acid O
( O
FA O
) O
gradient O
and O
Buffer O
B O
( O
80 O
% O
ACN O
with O
0.1 O
% O
FA O
) O
over O
60 O
min O
. O

Column O
washes O
were O
performed O
on O
a O
30 O
% O
–90 O
% O
acetonitrile O
in O
0.1 O
% O
formic O
acid O
gradient O
for O
2 O
min O
. O

The O
IonMax O
electrospray O
ion O
source O
settings O
were O
: O
spray O
voltage O
, O
+1900 O
V O
and O
capillary O
temperature O
, O
+250 O
°C O
. O

In O
the O
PRM O
method O
, O
we O
only O
observed O
charge O
states O
as O
described O
in O
the O
inclusion O
list O
and O
skyline O
file O
. O

The O
targeted O
MS/MS O
was O
run O
at O
an O
Orbitrap O
resolution O
of O
30,000 O
at O
m/z O
200 O
, O
an O
AGC O
target O
value O
of O
2 O
× O
105 O
, O
and O
maximum O
fill O
times O
of O
100 O
ms O
. O

The O
targeted O
peptide O
was O
isolated O
using O
a O
0.8 O
m/z O
unit O
window O
. O

Fragmentation O
was O
performed O
with O
normalized O
collision O
energy O
( O
NCE O
) O
of O
32 O
eV O
. O

In O
the O
PRM O
method O
, O
we O
only O
observed O
charge O
states O
as O
described O
in O
the O
inclusion O
list O
and O
skyline O
file O
. O

Seven O
peptides O
and O
their O
corresponding O
heavy O
peptides O
( O
Table O
4 O
) O
were O
comprised O
in O
the O
inclusion O
list O
. O

Target O
peptides O
were O
selected O
based O
on O
in O
silico O
cleavage O
of O
the O
proteins O
using O
the O
Peptide O
Mass O
feature O
of O
ExPASy O
bioinformatics O
portal O
( O
http O
: O
//web.expasy.org/peptide_mass/ O
) O
. O

The O
following O
settings O
were O
used O
: O
enzyme O
( O
trypsin O
) O
; O
0 O
missed O
cleavage O
and O
display O
the O
peptides O
with O
a O
mass O
bigger O
than O
500 O
Da O
. O

2.7 O
. O

PRM O
data O
analysis O
Mass O
spectrometry O
analysis O
was O
performed O
at O
the O
SPARC O
Biocentre O
( O
The O
Hospital O
for O
Sick O
Children O
; O
SickKids O
, O
Toronto O
) O
. O

We O
attempted O
to O
quantify O
4 O
and O
3 O
unique O
peptides O
for O
D2R O
and O
D3R O
, O
respectively O
( O
see O
Table O
4 O
) O
. O

However O
, O
because O
of O
the O
relatively O
low O
protein O
yield O
in O
our O
FFPE O
slide O
samples O
, O
only O
a O
single O
unique O
peptide O
of O
either O
protein O
was O
detected O
and O
subsequently O
used O
for O
identification O
. O

Data O
analysis O
and O
quantification O
of O
PRM O
runs O
was O
performed O
using O
Skyline O
software O
. O

Relative O
quantification O
of O
D2R O
and O
D3R O
peptides O
from O
schizophrenia O
patient O
and O
control O
samples O
was O
based O
on O
the O
sum O
of O
the O
area O
under O
the O
curves O
( O
AUC O
) O
of O
the O
top O
three O
most O
intense O
peptide O
fragments O
. O

The O
use O
of O
a O
subset O
of O
three O
to O
six O
fragment O
ions O
( O
with O
acceptable O
peak O
purity O
) O
for O
peptide O
quantitation O
has O
been O
previously O
suggested O
to O
yield O
more O
accurate O
results O
than O
the O
entire O
set O
. O

Endogenous O
peptides O
were O
matched O
to O
heavy O
isotope O
peptides O
based O
on O
their O
similar O
retention O
times O
and O
transition O
patterns O
. O

2.8 O
. O

Statistical O
analyses O
Statistical O
analyses O
were O
performed O
using O
IBM O
SPSS O
( O
v.20 O
) O
and O
GraphPad O
( O
v.5.0 O
; O
GraphPad O
Software O
, O
La O
Jolla O
California O
) O
. O

Normality O
of O
variables O
was O
determined O
using O
the O
D'Agostino-Pearson O
test O
. O

The O
significance O
level O
for O
all O
tests O
was O
set O
at O
p O
< O
.05 O
( O
two-tailed O
) O
. O

